title: Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin.
abstract: Interferons (IFNs) play an important role in immune surveillance of tumors; however, their efficacy in the treatment of malignancies has been limited. Monocytes are mononuclear phagocytes that are critical to the generation of an innate immune response to tumors. The authors and others have shown that treatment of tumor cell lines in vitro and in vivo with human monocytes primed with type I and type II IFNs results in killing. We now expand on this work, in an extended panel of ovarian cancer cell lines. In this study, we hypothesized that there would be variable sensitivity amongst cell lines to the killing properties of monocytes and IFNs. To this end, we explored the interactions of IFN primed monocytes in conjunction with the standard of therapy for ovarian cancer, taxane, and platinum-based chemotherapeutics. Using 6 ovarian cancer cell lines, we demonstrated that there is variation from cell line to cell line in the ability of IFN-α2a and IFN-γ primed monocytes to synergistically kill target tumor cells, and further, there is an additive killing effect when target cells are treated with both IFN primed monocytes and chemotherapy.
authors: Cytokine Biology Section, National Institute of Allergy and Infectious Diseases , National Institutes of Health, Bethesda, Maryland.
authors: Chase L
authors: CL
authors: Johnson
authors: Daniel S
authors: DS
authors: Green
authors: Kathryn C
authors: KC
authors: Zoon
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D016190:Carboplatin / Q000627:therapeutic use; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D016260:Monocytes, Activated Killer / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D017239:Paclitaxel / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D007371:Interferon-gamma; D016190:Carboplatin; D017239:Paclitaxel